Erlotinib may confer an economic advantage for payers over docetaxel and pemetrexed for second-line treatment of lung cancer because of lower costs.
Stephen Lash, PharmD
Advertisement
Articles by Stephen Lash, PharmD
Advertisement
Latest Updated Articles
- Costs Associated With Second-Line Therapies for Lung Cancer
Published: February 2nd 2011 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Regular Melatonin Supplementation May Hide Hidden Heart Complications
2
From Type 1 to Type 2 and Beyond: Navigating the Landscape of Diabetes
3
FDA Announces Recall 580,000 Bottles of Prazosin Over Potential Carcinogenic Impurity
4
COVID-19 Reinfection Heightens Risk of Postacute Sequelae of SARS-CoV-2 in Pediatrics
5
